miRNA-18a screened based on CRISPR can regulate targeted therapy resistance and T-cell killing in melanoma

In melanoma, the knockout of miR-18a not only leads to resistance to monotherapy with BRAF inhibitors but also to combined therapy with BRAF and MEK inhibitors. This resistance is achieved by promoting the expression of YAP in the Hippo pathway. Additionally, the knockout of miR-18a results in high expression of THBS1-CD47, which causes T cell tolerance. miR-18a is regulated by hnRNPA1, and patients with low expression of miR-18a and hnRNPA1 have poorer Event-Free Survival (EFS).